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Abstract: The human P2X7 receptor is a trimeric ligand-gated cation channel coded by the P2RX7
gene located at chromosome position 12q24. P2X7 is expressed in a wide variety of normal and
disease-associated cell types. Activation of this receptor by extracellular adenosine 5’-triphosphate
results in numerous downstream events including the release of pro-inflammatory mediators, cell
proliferation or death, and killing of intracellular pathogens. As a result, P2X7 plays important roles
in inflammation, immunity, bone homeostasis, neurological function and neoplasia. The P2RX7
gene encodes a P2X7 subunit 595 amino acids in length, however splice isoforms that can alter
receptor expression and function, and modify the signaling properties downstream of receptor
activation also exist. Moreover, the relative amount of P2X7 function varies between human
individuals due to numerous single nucleotide polymorphisms resulting in either loss- or gain-offunction. Combinations of these polymorphisms give rise to various haplotypes that can also
modify P2X7 function. Collectively, P2X7, and its splice and polymorphic variants are attracting
considerable interest in relation to human health and disease, including the development and
publication of a number of patents.
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INTRODUCTION

Extracellular nucleotides and nucleosides operate through a complex network of purinergic
signaling cascades involving various membrane receptors and ectoenzymes [1, 2]. One member of
this network is the P2X7 receptor, a trimeric ligand-gated cation channel encoded by the P2RX7
gene (purinergic receptor P2X, ligand-gated ion channel 7) and belonging to the P2X receptor
family [3, 4]. Activation of P2X7 by extracellular adenosine 5’-triphosphate (ATP) causes the
movement of Ca2+, Na+ and K+ across the plasma membrane, as well as the uptake of organic
cations including fluorescent dyes [3, 4]. P2X7 activation induces an array of downstream events, in
a cell specific manner, including the release of pro-inflammatory mediators [5], cell proliferation or
death [6], and killing of intracellular pathogens [7]. P2X7 is predominately expressed on cells of the
hematopoietic, epithelial, mesenchymal and neural lineages [8]. Subsequently P2X7 plays
important roles in inflammation, immunity, bone homeostasis, neurological function (including
pain) and neoplasia. Moreover, the relative amount of P2X7 expression and/or function varies
between human individuals, which can be explained in part by splice and polymorphic variants. Of
note, a number of these variants have been associated with diseases. This review will summarize the
biology of P2X7 including splice and polymorphic P2X7 variants, and detail recent patents relating
to DNA and gene sequences of P2RX7. Recent patents relating to P2X7 antagonists and their
relevance to human health and disease have been discussed elsewhere [9, 10].

THE P2X7 RECEPTOR

The P2X7 receptor is a trimeric ATP-gated cation channel comprised of homomeric
subunits 595 amino acids in length [11]. Each subunit comprises intracellular amino and carboxyl
termini with two hydrophobic transmembrane domains, separated by a long glycosylated
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extracellular loop containing ATP-binding sites [12, 13]. These observations are supported by
atomic computing modeling of the human P2X7 receptor [14], based on a crystal structure of the
zebrafish P2X4 receptor [15]. P2X7 subunits may also combine with P2X4 subunits to form
heteromeric receptors [16], however homomeric P2X7 receptors appear to be the dominant subtype
in most cell types [11, 17].
P2X7 was originally thought to be restricted to cells of the hematopoietic lineages, however
it is now evident that P2X7 is also present in other cell lineages. In regards to hematopoietic
lineages in humans, P2X7 is present (in decreasing amounts) on macrophages, dendritic cells,
monocytes, natural killer cells, B-lymphocytes, T-lymphocytes and erythrocytes [18-21]. P2X7 is
also present on human mast cells [22], microglia [23], osteoclasts [24], and eosinophils [25]. The
relative amounts of this receptor, however, in these latter cell types in relation to other human
hematopoietic cell types remain unknown. Despite the presence of P2X7 on eosinophils, human
neutrophils appear to be devoid of P2X7 [26, 27]. P2X7 is also present on other human cell types
including osteoblasts [28], fibroblasts [29], endothelial cells [30], and epithelial cells residing in
various tissues including the skin, cervix, pancreas and colon (see [31, 32] and references therein).
Moreover, P2X7 is present on various neural cell types including astrocytes, oligodendrocytes,
Schwann cells and neurons, however its precise localization and expression in the latter remains
controversial (see [33, 34] and references therein). Finally, P2X7 is present in various neoplastic
cells particularly those arising from hematopoietic and epithelial lineages (see [35, 36] and
references therein).
P2X7 activation induces a number of well-established downstream signaling events in
various human cell types (Fig. 1), many of which were originally established or have been
supported by studies in animal models. The best described signaling event downstream of P2X7
activation is the activation of the NALP3 inflammasome resulting in the functional maturation and
release of the pro-inflammatory cytokines, interleukin (IL)-1β and IL-18 from human myeloid cells
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(reviewed by [37]). Depending on the cell type, environmental conditions and concentration of
extracellular ATP, P2X7 activation can also promote cell proliferation or induce cell death via a
number of different intracellular pathways (reviewed by [6]). Moreover, P2X7 activation can
induce phagosome-lysosome fusion resulting in the killing of intracellular mycobacteria, chlamydia
and toxoplasma residing with human macrophages (reviewed by [7]). P2X7 activation can also
induce the release of CD21 (complement component receptor 2), CD23 (low affinity IgE receptor),
CD62L (L-selectin), matrix metalloproteinase 9 (gelatinase B) and cathepsins from lymphoid and
myeloid [18, 20, 38-43]; however the mechanisms linking P2X7 to these processes remain poorly
defined. Finally, P2X7 activation can induce other downstream signaling events in cells of various
lineages including rapid and reversible phosphatidylserine exposure, membrane blebbing, release of
microparticles and exosomes, and multinucleated cell formation (reviewed by [44]), as well as the
formation of reactive oxygen and nitrogen species (reviewed by [45]).

THE HUMAN P2RX7 GENE

The human P2RX7 gene comprises 13 exons and is located at chromosome position 12q24
[46], a region associated with inflammatory and psychiatric disorders [47, 48]. Initially, a putative
1.8-kb promoter region upstream of exon 1 was proposed [49], however experimental evidence
supporting this has been lacking. More recently, the transcription initiation site and an active
promoter region have been located 91 nucleotides, and 249 to 59 nucleotides respectively upstream
of exon 1 [50]. Furthermore, target sites for the microRNAs, miR-150 and miR-186 have been
identified within the P2RX7 3'-untranslated region, which can negatively regulate P2X7 mRNA
translation or P2X7 expression [51]. Putative microRNA binding sites within the P2RX7 3'untranslated region have also been found for miR-625, miR-1275, miR-491-5p and miR-1302 [52],
but direct evidence in relation to P2X7 expression is lacking. P2RX7 gene expression may also be
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modulated by other mechanisms including cis-enhancement and hypermethylation as reviewed
elsewhere [32].

P2X7 SPLICE ISOFORMS

A number of splice isoforms of the human P2X7 receptor have been identified (Fig. 2).
Initially, seven variants of human P2X7, resulting from alternative splicing, were identified [53].
These were designated as P2X7B to P2X7H by the investigators, with the original, full-length
receptor encoding 595 amino acids [12] defined as P2X7A. P2X7B includes the intron between
exons 10 and 11 leading to a new stop codon and a truncated protein lacking the last 171 amino
acids of the full-length protein, but containing an alternate 18 amino acids following the second
transmembrane domain. P2X7C to P2X7F lack various exons coding the parts of the extracellular
domain (exons 4, 5, 7 and 8, and 4 and 8 respectively); P2X7C and P2X7E also contain the same
intron between exons 10 and 11 as P2X7B. P2X7G and P2X7H contain an additional exon (termed
exon N3) in the intron between exons 2 and 3, which introduces a new start codon potentially
leading to translation of a P2X7 protein lacking the first transmembrane domain. P2X7G also
contains the same intron between exons 10 and 11 as P2X7B, P2X7C and P2X7E. Thus, four of the
seven splice isoforms of P2X7 have an alternate short carboxyl terminus, while two potentially lack
the first transmembrane domain.
Of the above P2X7 variants, two (P2X7B and P2X7H) have been studied in greater detail.
P2X7B shares a similar tissue distribution to the full-length receptor (P2X7A), with P2X7B mRNA
expressed at comparable or greater amounts than P2X7A mRNA [53, 54]. The relative distribution
and amounts of these P2X7 isoforms however, are yet to be compared at the protein level.
Functional comparisons to P2X7A, demonstrated that P2X7B can form functional channels but not
pores, and is a poor inducer of caspase-3 and -7 activation [53, 54]. Co-expression of P2X7B with
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P2X7A however, results in heteromeric receptors that increase the intracellular ATP content and
endoplasmic reticulum Ca2+ content to activate NFATc1 and stimulate cell growth [54].
Collectively, these studies suggest that P2X7A and P2X7B have growth promoting activities, and
that P2X7A has additional roles in inflammation and cell death [54]. In contrast to P2X7A and
P2X7B, P2X7H is present at low amounts in tissues, and appears to be non-functional [53]. Despite
this progress, the specific relevance of these P2X7 splice isoforms to human health and disease
remains to be defined.
Three additional P2X7 variants have also been described. A ninth P2X7 variant was named
P2X7I [55], and results from a rare point mutation (rs35933842; g151+1>t) in the intron between
exons 1 and 2, leading to a null allele [56]. The significance of this null allele to human health and
disease is unknown. However, ATP-induced killing of mycobacteria is completely ablated in
macrophages from subjects heterozygous for both rs35933842 and a second loss-of-function P2RX7
allele (rs3751143; Glu496Ala) supporting a possible role for P2X7I in increased susceptibility to
tuberculosis. A tenth variant, P2X7J, has been described [55]. This P2X7 variant lacks exon 8
resulting in a truncated protein comprising 258 amino acids including an alternate 10 amino acids at
the C-terminus. P2X7J is non-functional, and when co-expressed with P2X7A results in the
formation of non-functional P2X7A/P2X7J heteromeric receptors. P2X7J is present in both normal
and malignant cervical tissue, with higher expression in the latter and leading to the suggestion that
this variant may protect malignant cells from ATP-induced apoptosis. Finally, an eleventh splice
variant, P2X7K, has been found in rodents resulting from an additional exon (termed exon 1’) in the
intron between exons 1 and 2, and leading to a receptor with an alternate N-terminus and first
transmembrane domain, with increased agonist sensitivity and propensity to form P2X7 pores [57].
However, to our knowledge this variant is yet to be described in humans.
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P2X7 SINGLE NUCLEOTIDE POLYMORPHISMS

A recent survey of the NCBI single nucleotide polymorphism (SNP) database
(http://www.ncbi.nlm.nih.gov/sites/entrez) has revealed that over 686 SNPs reside within the
human P2RX7 gene [58]. The majority of these SNPs however are intronic or synonymous. There
are 28 non-synonymous SNPs, of which only 16 have been characterized for phenotype (Table 1;
Fig. 3). Of these 16 SNPs, the loss-of-function P2RX7 SNP, rs3751143 (Glu496Ala) [59], has been
the most extensively studied (Table 2). As seen in Table 2, this SNP impairs a number of P2X7mediated processes in a variety of cell types. Although direct evidence is limited, it is likely that
similar functional defects may also occur for other loss-of-function P2RX7 SNPs. In this regard,
rs35933842 (g151+1>t), rs28360457 (Arg307Gln), rs2230911 (Thr357Ser) and rs1653624
(Ile568Asn) also impair ATP-induced apoptosis of macrophages and/or killing of intracellular
mycobacteria or toxoplasma [60-62]. Conversely, gain-of-function SNPs, rs208294 (His155Tyr),
rs7958311 (His270Arg) and rs1718119 (Ala348Thr), have been associated with increased ATPinduced IL-1β release from monocytes [63]. In contrast to most SNPs however, rs3751143 appears
unique in that the amino acid substitution impairs P2X7-mediated organic cation uptake (pore
function), but not P2X7-mediated currents (channel function) [64]. This observation has been
recently challenged [14], however we have argued [65] that the weight of experimental evidence
still favors the earlier observation [64].
Despite the phenotypic characterization of a number of P2RX7 SNPs, the mechanisms by
which the amino acid substitutions lead to altered function remain poorly understood. Amino acid
substitutions in the extracellular loop are proposed to alter ATP binding [14, 66, 67]. Consistent
with this hypothesis, rs28360457 codes for an amino acid substitution (Arg307Gln) [67] at a site
homologous to the putative ATP-binding sites in other P2X receptors [68]. Amino acid
substitutions in the transmembrane and C-terminus regions are thought to alter the gating properties
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of the channel and/or to disrupt channel or pore formation [59, 62, 63], although some evidence
exists that changes in the C-terminus can also alter ATP sensitivity [14]. In contrast, rs1653624
codes for an amino acid substitution (Ile568Asn) that prevents trafficking of P2X7 to the plasma
membrane and leads to a complete loss-of-function when present in homozygous dosage [69].

P2X7 SINGLE NUCLEOTIDE POLYMORPHISMS & DISEASE

P2RX7 SNPs have been associated with various diseases (Table 3). Of these, the association
of rs3751143 with increased susceptibility to tuberculosis is the most robust. Of the 10 cohorts
reported, 6 of these (from various racial groups) have found an increased frequency of the mutant
allele in this disease (see Table 3). Moreover, this association of rs3751143 with tuberculosis is
supported by meta-analysis [70]. The increased susceptibility of patients coding rs3751143 to
tuberculosis is most likely due to impaired P2X7-mediated killing of intracellular mycobacteria
within macrophages [60, 71, 72], however other mechanisms such as impaired IL-1β release [73] or
adaptive immune responses [74] cannot be excluded. The SNP rs3751143 has also been studied in
multiple cohorts comprising patients with chronic lymphocytic leukemia (CLL) following initial
observations that an increased frequency of rs3751143 may be associated with increased
susceptibility to or prolonged survival in CLL [75, 76]. Neither association however was supported
by additional studies [77-80] or by a meta-analysis of the combined studies [78]. Finally, an
increased frequency of the mutant rs2230912 allele has been associated with mood disorders
(bipolar or unipolar disorders) [81-85], however these findings have not been supported by other
studies [86-88]. The rs2230912 SNP has only a minor effect on P2X7 function [14, 63] and it is
currently difficult to reconcile how this SNP may be of physiological consequence in mood
disorders. We have recently demonstrated however, that this SNP is in linkage disequilibrium with
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three gain-of-function P2RX7 SNPs in a haplotype potentially leading to increased amounts of
circulating IL-1β and altering mood states [63].
The association of P2RX7 SNPs with other diseases has been examined in a variety of other
studies with many failing to find a significant association (Table 3). The majority of these studies
have small sample sizes and thus lack sufficient statistical power to detect if a significant
association exists. Future studies examining the association of P2RX7 SNPs with disease will
benefit from the development of high-through genotyping, and the collection of large disease
cohorts and appropriately matched controls. Moreover, future studies will need to consider the
combined effect of multiple P2RX7 SNPs or haplotypes. Nevertheless further studies of P2X7 in
relation to human health and disease are warranted based on observations in rodent models of
disease, as well as with clinical samples obtained from humans. For example, P2X7 and its variants
may play an important role in inflammatory and immune disorders such as rheumatoid arthritis.
ATP induces significantly higher amounts of IL-1β release in blood samples obtained from
rheumatoid arthritis patients compared to controls [89], while P2X7-deficient mice (Pfizer) have
reduced severity and incidence of anti-collagen antibody-induced arthritis [90]. Additionally, an
important role for P2X7 and its variants is suggested in relation to bone disorders. P2X7 is present
on both human osteoclasts and osteoblasts [24, 28], while P2X7-deficient mice (Pfizer) display
reduced bone formation and content [91]. A final example of the potential role of P2X7 and its
variants is indicated in neurodegenerative disorders such as multiple sclerosis. P2X7 expression is
expressed at higher amounts on spinal cord microglia from multiple sclerosis patients compared to
controls [92], while P2X7-deficient mice (Glaxo-Smith-Kline) have reduced incidence of
experimental autoimmune encephalomyelitis, a model of multiple sclerosis [93]. The role of P2X7
in multiple sclerosis however, is confounded by an earlier study showing that experimental
autoimmune encephalomyelitis is exacerbated in P2X7-deficient mice (Pfizer) [94].
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PATENTS REGARDING THE P2RX7 GENE & P2X7 VARIANTS

A number of patents have been filed relating to either splice or polymorphic variants of the
P2X7 receptor (Table 4). The majority of these patents outline claims for the detection of P2RX7
variants in various disorders. Other patents mostly outline claims relating to P2RX7 gene
expression.
Several patents have been filed in relation to P2RX7 SNPs. Patent US7767398 [95] claims a
method for diagnosing a mood (affective) disorder or susceptibility to a mood disorder in an
individual encoding rs2230912 or a deletion of that allele. This patent follows an earlier patent
(WO2004092384; [96]) of the same name undertaken by the same inventors. The claims of this
earlier patent are broader including regions in the 5’ untranslated region, and exons 5 and 8 of
P2RX7, as well as a number of other intronic and exonic P2XR7 SNPs. The association of
rs2230912 with mood disorders was originally shown by the inventors [81, 83] and subsequently
validated by others [84, 85], however as mentioned above others have failed to find an association
between this SNP and mood disorders [86-88]. Nonetheless, our recent data indicates that
rs2230912 lies in linkage disequilibrium with a gain-of-function haplotype [63] which may account
for the discordance between the various genetic studies of P2RX7 and mood disorders [65]. In
patent WO2010061246 [97], the inventors claim an in vitro method used to assess the sensitivity of
subjects to chemotherapeutic or radiotherapeutic treatment of cancer. This assay relies on the
detection of loss-of-function SNPs resulting in reduced function of the P2X7-elicited NALP3
inflammasome pathway. This patent includes the loss-of-function P2RX7 SNPs, rs28360457,
rs1653624, rs3751143 and rs2230911. This patent is based on recent data demonstrating a role for
tumor-derived ATP and P2X7-mediated IL-1β release from dendritic cells in anti-tumor immune
responses during chemotherapy. Treatment of human and murine cancer cells with a variety of
chemotherapeutic agents or γ-irradiation induces the release of ATP into the extracellular
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environment [74, 98, 99]. Moreover, in vitro and in vivo murine studies have shown that this ATP
can activate P2X7 on dendritic cells to stimulate the NALP3 inflammasome and the subsequent
release of biologically active IL-1β to generate interferon-γ producing anti-tumor CD8+ T-cells and
effective anti-tumor adaptive immunity [74]. Of clinical significance, the P2RX7 SNP, rs3751143
(Glu496Ala), which prevents ATP-induced IL-1β release [73], is associated with reduced metastatic
disease-free survival rates in breast cancer patients treated with anthracyclines [74]. Patent
US20090253585 [100] claims a genotyping method of predicting the susceptibility of a subject to
develop a somatosensory disorder based on the identification of at least one haplotype or SNP from
a very broad range of genes including P2RX7. This patent includes 16 P2RX7 SNPs (rs684201,
rs685019, rs208288, rs17525809, rs208294, rs16950860, rs7958311, rs1718136, rs1718119,
rs6489795, rs2230912, rs3751143, rs2230913, rs3751142, rs1621388 and rs1653625). Although a
number of animal studies support a role for P2X7 in tactile sensation, nociception and pain [101104], evidence for a role for P2X7 in somatosensory disorders in humans including the association
of loss- or gain-of-function P2XR7 SNPs is lacking. Patent US7205146 [105] claims a 12q23-qter
nucleotide sequence (and an assay for its detection) which contains the P2RX7 SNP, rs7958311.
Based on case-control association studies of North American and British cohorts [105], the
inventors report a significant over-representation of the adenine-containing variant of rs7958311
(coding for His at residue 270) in subjects with asthma, bronchial hyper-responsiveness or higher
IgE amounts. The frequency of other P2RX7 SNPs in this study were not significantly different
between controls and cases, and to the best of our knowledge this association study has not been
published in a peer-reviewed journal. Patent WO2006136791 [106] claims a method to identify a
P2XR7 haplotype containing rs169631 (intronic SNP; c>g) and rs3751143 in patients who are at
risk of atherosclerosis and atherosclerosis-mediated diseases or conditions such as myocardial
infarction. This genetic association is based on a cohort comprising 387 Swedish patients
hospitalized due to myocardial infarction [106], however to the best of our knowledge this
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association study has not been published in a peer-reviewed journal. Patent EP1741722 [107]
claims materials and methods for the identification of numerous P2RX7 SNPs including most of
those listed in Table 1. This patent is broad in its application with no apparent claims to any specific
disorders.
Given the potential significance of various P2RX7 SNPs in various disorders it has also been
of value to develop methods that can potentially identify subjects coding loss- or gain-of-function
SNPs or haplotypes based on a phenotypic parameter such as P2X7-mediated pore formation [108,
109]. Patents US7560243 [110] and US2009053204 [111] claim a flow cytometric-based assay to
measure the relative P2X7 function (pore formation) in peripheral blood monocytes. This method
has been extensively described [109, 112], and the measured pore formation correlates with the
capacity of monocytes to release altered ratios of tumor necrosis factor-α and IL-10 [113], and with
specific P2RX7 SNPs or haplotypes [114]. The potential clinical utility of this assay has been used
to identify subjects at risk of virus-induced loss of asthma control [115]. This study however, did
not report the P2RX7 genotype of the cohort. Thus, a direct correlation between clinical status or
pore formation to P2RX7 genotype could not be ascertained.
As an alternative to the detection of P2X7-mediated pore formation, the inventors of a series
of patents WO2010000041 [116], WO2009033233 [117], WO2008043145 [118], WO2008043146
[119], US7326415 [120] and WO2002057306 [121] claim the development of polyclonal and
monoclonal antibodies (and related reagents) capable of binding to non-functional P2X7. Nonfunctional receptors may result from non-synonymous SNPs in P2RX7 [122], however it is yet to be
determined if the developed antibodies recognize all or only a sub-group of these receptors. The
original antibody targeted an epitope within a loop adjacent to the extracellular ATP-binding site
(residues 193-214) [123], and was found to bind non-functional P2X7 (including those arising from
subjects carrying the rs3751143 mutant allele) but not to functional P2X7 [122]. Subsequently, it
was shown that this antibody could bind to cells in malignant but not normal tissue, and allowed for
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the differentiation of these two tissue states in melanoma, prostate cancer and breast cancer [124126].
Other patents relate to P2X7 isoforms. The inventors of patent US7767789 [127] claim
materials and methods to detect P2X7J mRNA and protein in normal and malignant tissue. This
claim relates to the inventors observations that P2X7J is over-expressed in certain epithelial
malignancies and promotes an anti-apoptotic phenotype [55]. The inventors of patent
WO2004090097 [128] claim a P2X7 isoform, HBMYP2X7v, containing a sequence of 1521
nucleotides and encoding a polypeptide of 506 amino acids. In addition, the inventors claim
methods relating to the detection of this variant in the diagnosis or treatment of a broad group of
neurological and neurodegenerative disorders. However, it remains to be determined if this isoform
leads to a product of functional significance or is of clinical relevance.
Finally, a number of patents relate to the expression of the P2RX7 gene product. The
inventors of patents US20090232893 [129], US20090227533 [130], US20090175827 [131] and
US2009163434 [132] claim that miR-143, miR-34, miR-16 and miR-20 respectively modulate the
expression of a large number of gene products, including P2X7, in a very broad group of disorders
involving most of the systems within the body. Patent WO2008115387 [133] is more specific. The
inventors of this patent claim the use of miR-150 and miR-186 as potential biomarkers in the
management of uterine malignancies. This claim relates to data demonstrating that over-expression
of these microRNAs in malignant uterine tissue down-regulates P2X7 and subsequently reduces
ATP-induced apoptosis [51]. Conversely, patent WO2006024880 [134] claims the use of short
inhibitory RNA (siRNA) to down-regulate P2X7 in patients from a very broad group of disorders
including those of the neuronal, cardiovascular, inflammatory, cutaneous and renal systems. The
potential utility of this application has been demonstrated by others using rats, where in vivo
administration of siRNA to P2X7 impairs spinal nociceptive responses [135]. Finally, the inventors
of WO2008142194 [136] claim a molecular-based method for measuring the P2RX7 gene product
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in the diagnosis and prognosis of Huntington’s disease. This claim relates to data outlining evidence
for increased P2X7 expression and function (Ca2+ flux and cell death) in neurons of mouse models
of Huntington’s disease [137]. Evidence however for a role for P2X7 in Huntington’s disease in
humans is lacking.

CURRENT & FUTURE DEVELOPMENTS

Splice and polymorphic variants of P2X7 are attracting considerable attention in human
health and disease resulting in a number of related patents. Due to the prior publication of P2RX7
and its isoforms and SNPs, the majority of patents relating to P2X7 claim the detection of P2RX7
variants in specific or broadly specified disorders, rather than nucleotide sequences of P2RX7. This
prior identification and publication of P2RX7 isoforms and SNPs independently of patents has
greatly assisted and most likely expedited our understanding of P2X7 in human physiology and
pathophysiology. Nevertheless the scientific merit and utility of current and future patents relating
to the P2RX7 gene will need to be validated by larger sample sizes and examination by other
investigators. It will also need to be determined if the relevance of such patents is restricted to
specific racial groups or whether they have broader or universal application within the human
population. In this regard, it still remains to be determined if many of the currently known P2RX7
isoforms and SNPs exist in less-well studied human groups. Conversely, it remains to be
determined if novel P2RX7 variants exist in such groups. Moreover, given the highly polymorphic
nature of the P2XR7 gene and its receptor, future genetic association studies will need to include the
analysis of P2RX7 haplotypes and the detailed phenotypic characterization of the encoded
receptors. Included in this, is the further understanding of the mechanisms by which P2RX7 SNPs
alter receptor expression and function including events downstream of P2X7 activation, and
whether these SNPs have similar effects on P2RX7 splice isoforms particularly P2X7B. It will also
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be of importance to determine the relative effectiveness of P2X7 therapeutics, currently under
development or in clinical trials [9, 10], in relation to P2X7 isoforms and polymorphic variants.
Finally, given that much of our understanding of P2X7 is inferred from rodent models of
inflammatory, immune, bone, and neurological disorders, as well as pain, it will be important to
directly establish a role for P2X7 in these and other human diseases to help develop and validate the
claims of current and future patents.
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FIGURE LEGENDS
Fig. (1). Signaling events downstream of human P2X7 receptor activation. P2X7 is a trimeric
ligand-gated cation channel (only one P2X7 subunit is shown). Activation of P2X7 by extracellular
adenosine 5’-triphosphate (ATP) induces a number of downstream signaling events, as illustrated,
in a variety of cell types. IL, interleukin; MMP-9, matrix metalloproteinase 9; PS,
phosphatidylserine; RONS, reactive oxygen and nitrogen species.

Fig. (2). Splice isoforms of the human P2X7 receptor. Top schematic representation shows the
domains of the full-length human P2X7 receptor including the first (TM1) and second (TM2)
transmembrane domains. Remaining schematic representations show the regions encoding the
original, full-length human P2X7 receptor (P2X7A) and its splice isoforms (P2X7B to P2X7K).
Numbered boxes and solid lines represent exons and alternate coding regions respectively.
Additional exons, 1’ and N3, present in the introns (not shown) between exons 1 and 2, and exons 2
and 3 respectively, are termed as originally described [55, 57]. The additional exon in P2X7G and
P2X7H introduces a new start codon potentially leading to translation of a P2X7 protein lacking the
first transmembrane domain. *To date P2X7K has been observed only in rodents. Schematic
representations of the P2X7 isoforms are adapted from previous studies [53, 55].

Fig. (3). Characterized single nucleotide polymorphisms of the human P2RX7 gene. Schematic
representations of the human (A) P2XR7 gene and (B) P2X7 subunit displaying single nucleotide
polymorphisms. (A) Solid lines and numbered boxes represent introns (not to scale) and exons
respectively. An additional exon, N3, in the intron between exons 2 and 3 is not shown. (B) Open
circles, closed triangles and closed circles represent gain-, partial loss- and loss-of-function
polymorphisms respectively; the open triangle represents a polymorphism with neutral effect on
P2X7 function, but reduced sensitivity to inhibition by extracellular Ca2+. SNP rs35933842, which
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leads to a null allele, is located in the intron between exons 1 and 2, and thus is not shown in the
P2X7 subunit. Schematic representation of the human P2X7 subunit is adapted from a schematic of
the murine P2X7 subunit of a previous study [138].
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Table 1. Characterized Single Nucleotide Polymorphisms of the Human P2RX7 Gene.
dbSNP ID

Base change
gt>tt
GTG>GCG
CGG>TGG
GGA>AGA
CAT>TAT

Amino Acid
change
Val76Ala
Arg117Trp
Gly150Arg
His155Tyr

Effect on
function
Loss
Partial loss
Loss
Loss
Gain

Minor Allele
Frequency1
0.008
0.062
nd
0.018
0.439

rs35933842
rs17525809
rs28360445
rs28360447
rs208294
rs28360451
rs28360452
rs7958311
rs7958316
rs28360457
rs1718119

GAA>AAA
CTC>CCC
CAT>CGT
CGT>CAT
CGG>CAG
GCT>ACT

Glu186Lys
Leu191Pro
His270Arg
Arg276His
Arg307Gln
Ala348Thr

Loss
Loss
Gain
Loss
Loss
Gain

nd
nd
0.255
0.020
0.013
0.400

rs2230911
rs2230912
rs3751143

ACT>AGT
CAG>CGG
GAG>GCG

Thr357Ser
Gln460Arg
Glu496Ala

Partial loss
Partial loss
Loss

0.083
0.170
0.175

Reference
[56]
[14, 63]
[14]
[14, 63]
[14, 58,
63, 66,
139]
[14]
[14]
[63]
[63]
[67]
[14, 58,
63]
[62]
[63]
[14, 58,
59]
[14]
[14, 69]
rs2230913

rs2230913
CAC>CAG
His521Gln
Neutral2
0.020
rs1653624
ATC>AAC
Ile568Asn
Loss
0.029
1
Minor
allele
frequencies
were
previously
described
[63]
except
(http://www.ncbi.nlm.nih.gov/projects/SNP); nd, not determined.
2
Neutral effect; however the mutant receptor displays reduced sensitivity to inhibition by
extracellular Ca2+.
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Table 2. Functional Defects of the rs3751143 (Glu496Ala) Single Nucleotide Polymorphism
Functional Defect
Ba (Ca2+), Rb+ (K+) flux
2+

Ethidium+, Yo-Pro-12+
uptake
CD23 shedding
CD62L shedding
IL-1β release
IL-18 release
TNF-α/IL-10 ratio
Matrix metalloproteinase 9
release
Phosphatidylserine
exposure
Phospholipase D activation
Mycobacterial killing
Toxoplasma killing
Cell death

Cell Types
Monocytes, B- and T-lymphocytes,
erythrocytes
Macrophages, dendritic cells,
Langerhans cells, monocytes, natural
killer cells, B- and T-lymphocytes
Dendritic cells, Langerhans cells
Monocytes, lymphocytes
Monocytes
Monocytes
Whole blood
Monocytes, B- and T-lymphocytes

[18, 20, 59, 60, 71-73, 76,
108, 109, 112-114, 122,
141]
[18, 20]
[73]
[73]
[141]
[113]
[40]

Erythrocytes

[142]

B-lymphocytes
Macrophages
Macrophages
Macrophages, B- and T-lymphocytes

[143]
[60, 71, 72]
[61]
[59, 60, 71, 72, 76]
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References
[59, 73, 108, 140]

Table 3. Association of P2RX7 Single Nucleotide Polymorphisms with Human Disorders
Disorder

Associated
Allele(s)1

Accelerated
Lumbar Spine
Bone Loss

rs28360457

Fracture risk

rs3751143,
rs1653624

Hip geometry
Periprosthetic
osteolysis

rs28360457
(increase hip
arthroplasty
failure risk)

Allogeneic stem
cell
transplantation

rs3751143
(reduced
survival due to
infection)
rs1718119

NonPopulation
associated
Allele(s)2
Bone Disorders
rs35933842,
Scottish postrs28360447
menopausal
rs3751143,
women
rs1653624
rs28360457
Danish
rs3751143,
rs1653624
rs35933842,
rs3751143,
rs1653624

References

[144]

[145]

Danish

[146]

Czech

[147]

Korean

[148]

North American,
Brazilian
Gambian
Asian Indian

[149]

Chinese Han

[151]

Infectious Diseases

Toxoplasmosis
Tuberculosis
Tuberculosis

rs2393799 (↓)
rs2393799,
rs1653624 (↓)

Tuberculosis
Tuberculosis
Tuberculosis
Tuberculosis
Tuberculosis
Tuberculosis
Tuberculosis
Tuberculosis
Tuberculosis
Ambulatory
blood pressure
Crohn’s disease
Heart failure
Rheumatoid

rs3751143
rs3751143
rs2393799,
rs3751143
rs3751143
rs2393799
rs2393799

Peruvian
Various3
Mexican
Mestizo
rs3751143
rs2393799
Russian
Caucasian
rs3751143
Australian
Vietnamese
rs3751143
Australian Asian
rs3751143
Turkish children
rs3751143
Punjabi
Inflammatory and cardiovascular disorders
rs591874
13 other
British
rs3751143
rs3751143

rs208294,
rs28360457,
rs3751143
rs3751143
rs2393799,
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[49]
[150]

[152]
[70]
[153]
[154]
[71]
[71]
[155]
[156]
[157]

German

[158]

Australian
Mexican

[159]
[160]

arthritis
Sjögren’s
Syndrome

rs3751143
rs2230912
(increased
Ro/La
autoantibody
diversification)

Systemic lupus
erythematosus
Systemic lupus
erythematosus

Australian

[161]

Mexican

[160]

Australian,
Italian

[162]

French

[74]

Swedish

[75]

Australian

[76]

rs3751143

German

[77]

rs3751143

British, various4

[78]

rs3751143

British

[79]

rs3751143

British

[80]

Australian,
British

[163]

rs3751143

British

[78]

rs3751143

British

[164]

Tunisian

[165]

Italian

[166]

rs2393799,
rs3751143
rs3751143
Malignancies

Breast cancer
(anthracylinetreated)
Chronic
lymphocytic
leukemia
Chronic
lymphocytic
leukemia
Chronic
lymphocytic
leukemia
Chronic
lymphocytic
leukemia
Chronic
lymphocytic
leukemia
Chronic
lymphocytic
leukemia
Chronic
lymphocytic
leukemia
(familial)
Chronic
lymphocytic
leukemia
(familial)
Multiple
myeloma
Nasopharyngeal
carcinoma
Papillary thyroid
cancer

rs3751143
(reduced
metastatic-free
survival)
rs3751143
(increased
survival)
rs3751143

rs3751143

rs3751143
(increased
autoantibodies)
rs3751143
(follicular
variant only)

rs208294
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Anxiety

rs1718119

Bipolar disorder

rs2230912

Bipolar or
unipolar
disorder

rs2230912

Bipolar or
unipolar
disorder
Bipolar or
unipolar
disorder
Bipolar or
unipolar
Bipolar or
unipolar
disorder
Unipolar
disorder
Unipolar
disorder
Unipolar
disorder
Schizophrenia

rs2230912
(increased
clinical score)
rs1653625

Psychiatric Disorders
rs2230912
German
plus 10 other
16 other
French
Canadian
rs208293,
British
rs208294
rs504677
rs1718119
Hungarian

rs2230912
plus 8 other
rs2230912
rs2230912

15 other

rs2230912
rs2230912

[167]
[81]
[84]

[82]

Hungarian

[52]

British

[86]

German, Polish,
Romanian,
Russian
German
Caucasian
Hungarian
diabetics
Swedish

[87]
[83]
[85]
[88]

rs2230912
Danish
[168]
plus 8 other
1
Allele frequency significantly greater in cases compared to controls unless otherwise indicated (↓);
comments in parenthesis indicate that the allele frequency was not significantly different between
cases and controls, but correlated with specified clinical parameters.
2
Allele frequency not significantly different between cases and controls.
3
Meta-analysis of multiple studies (see corresponding reference for details).
4
Includes meta-analysis of multiple studies (see corresponding reference for details).
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Table 4. Patents Related to the P2RX7 Gene and P2X7 Variants.
Publication
Number
US7767789
US7767398

Reference Number and Title

Inventors

[127] Truncated proteins as cancer
markers
[95] Means and methods for diagnosing
and treating affective disorders

Gorodeski, G.,
Feng, Y-H., Li, X.
Barden, N.,
Sillaber, I., PaezPereda, M.
Apetoh, L.,
Tesniere, A.,
Ghiringhelli, F.,
Zitvogel, L.,
Kroemer, G.
Barden, J.A.,
Gidley-Baird, A.
Diatchenko, L.,
Maixner, W.

WO2010061246

[97] Use of P2X7 pathway for assessing
the sensitivity of a subject to a cancer
treatment

WO2010000041

[116] Anti-P2X7 peptides and epitopes

US20090253585

[100] Identification of genetic
polymorphic variants associated with
somatosensory disorders and methods of
using the same
[129] Mir-143 regulated genes and
pathways as targets for therapeutic
intervention

US20090232893

US20090227533

[130] Mir-34 regulated genes and
pathways as targets for therapeutic
intervention

US7560243

[110] White blood cell functional assay

US20090175827

[131] Mir-16 regulated genes and
pathways as targets for therapeutic
intervention

US20090163434

[132] Mir-20 regulated genes and
pathways as targets for therapeutic
intervention

WO2009033233

[117] Novel P2X7 epitopes

US2009053204

[111] Functional genomic pore assay for
mixed cell populations
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Bader, A.G.,
Byrom, M.,
Johnson, C.D.,
Brown, D.
Bader, A.G.,
Patrawala, L.,
Wiggins, J.F.,
Byrom, M.W.,
Johnson, C.D.,
Brown, D.
Denlinger, L.C.,
Hogan, K.J.,
Bertics, P.J.,
Schell, K.
Byrom, M.,
Patrawala, L.,
Johnson, C.D.,
Brown, D., Bader,
A.G.
Bader, A.G.,
Byrom, M.,
Johnson, C.D.,
Brown, D.
Barden,
J.A.,Gidley-Baird,
A.
Denlinger, L.C.,
Hogan, K.J.,
Bertics, P.J.,
Schell, K.

Publication
Date
2010/08/03
2010/08/03
2010/06/03

2010/01/07
2009/10/08

2009/09/17

2009/09/10

2009/07/14

2009/07/09

2009/06/25

2009/03/09
2009/02/26

WO2008142194

[136] Method for the in vitro
diagnosis/prognosis of Huntington's
chorea

WO2008115387

[133] Screening, diagnosing, treating and
prognosis of pathophysiologic status by
RNA regulation
[118] Hybridomas producing antibodies
against non functional P2X7 receptor
[119] Antibodies against non-functional
P2X7 receptor
[120] Antibodies to non-functional P2X7
receptor
[107] Polymorphisms in the human P2X7
gene
[134] Methods and compositions to inhibit
P2X7 receptor expression

WO2008043145
WO2008043146
US7326415
EP1741722
WO2006024880

US7205146

[105] Nucleotide and amino acid
sequences relating to respiratory diseases
and obesity

WO2006136791

[106] Polymorphisms and haplotypes in
P2X7 gene and their use in determining
susceptibility for atherosclerosis-mediated
diseases
[96] Means and methods for diagnosing
and treating affective disorders

WO2004092384
WO2004090097

[128] Polynucleotide encoding a novel
human P2X7 splice variant, HBMYP2X7v

WO2002057306

[121] Antibodies to non-functional P2X7
receptor diagnosis and treatment of
cancers and other conditions
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2006/03/09

2008/09/25
2008/04/17
2008/04/17
2008/02/05
2007/01/10

2007/04/17

2006/12/28

2004/10/28
2004/10/21

2002/07/17

IL-1β and IL-18
maturation and
release

Killing of
intracellular
pathogens
Cell proliferation
or death

RONS formation

Multinucleated
cell formation

P2X7 ATP

Microparticle and
exosome release

Membrane
blebbing

Shedding of
CD21, CD23 and
CD62L
Release of
MMP-9 and
cathepsins

Rapid and
reversible PS
exposure

Amino
terminus TM1

Extracellular
loop

Carboxyl
terminus

TM2

P2X7A

1

2

3 4

5 6

7

8

9 10 11 12

P2X7B

1

2

3 4 5 6

7

8

9 10

P2X7C
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3 5 6
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1

2

3 5 6
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8

9 10
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7

8
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1

P2X7J
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8
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7

8

9 10

8
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13

His155Tyr
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His270Arg

Val76Ala

3’
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9 10
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8
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7

rs28360457
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rs7958316
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5
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4
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3
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